13 documents

Read All
07:00 , Aug 21, 2006 |  BioCentury  |  Strategy

Targeted Genetics chronicles

Targeted Genetics chronicles Selected events tracked against Targeted Genetics' weekly stock price since the company's IPO in 1994. Y-axis = log scale A. 5/20/94 - Raises $12M in IPOB. 7/14/95 - Raises $11.7M in private...
Read More
07:00 , Aug 21, 2006 |  BioCentury  |  Strategy

Learning through time

Gene therapy was supposed to be easy: find a disease caused by a single gene defect and replace the gene. After the NIH showed proof-of-principle with severe combined immune deficiency (SCID) in 1990, the diseases...
Read More
07:00 , Aug 2, 2004 |  BC Week In Review  |  Company News

Chromos, Targeted Genetics deal

CHR completed the acquisition of TGEN subsidiary CellExSys Inc. (Seattle, Wash.) for about C$4.5 million (US$3.4 million) (see BioCentury, June 28). TGEN owned about 80% of CellExSys. The other shareholders were mainly CellExSys employees and...
Read More
07:00 , Jun 28, 2004 |  BC Week In Review  |  Company News

Chromos, Targeted Genetics deal

CHR will acquire all of the outstanding shares of TGEN's majority-owned subsidiary CellExSys Inc. (Seattle, Wash.) for about C$4.5 million (US$3.3 million). The payment comprises 1.5 million CHR shares and a two-year convertible debenture worth...
Read More
07:00 , Oct 14, 2002 |  BC Week In Review  |  Company News

Targeted Genetics Inc., Itochu Corp. deal

TGEN majority-owned subsidiary CellExSys Inc. (Seattle, Wash.) partnered with Itochu to form a Japanese joint venture to develop, commercialize and manufacture CellExSys's cell therapy products in Japan. CellExSys received an undisclosed upfront payment from Itochu....
Read More
07:00 , Oct 10, 2002 |  BC Extra  |  Company News

CellExSys, Itochu forming cell therapy JV

CellExSys (Seattle, Wash.), a majority-owned subsidiary of Targeted Genetics (TGEN), partnered with Itochu (Tokyo, Japan) to form a Japanese joint venture to develop, commercialize and manufacture CellExSys's cell therapy products in Japan. CellExSys received an...
Read More
08:00 , Dec 3, 2001 |  BC Week In Review  |  Clinical News

T cell expansion technology regulatory update

TGEN's CellExSys Inc. majority owned subsidiary received U.S. Patent No. 6,316,257 covering in vitro production of antigen-specific T cells. The patent relates to CellExSys' Rapid Expansion Method (REM) technology for in vitro T cell expansion....
Read More
07:00 , Jul 16, 2001 |  BC Week In Review  |  Company News

Targeted Genetics management update

Targeted Genetics Corp. (TGEN), Seattle, Wash.   Business: Gene/Cell therapy   Hired: Phillip Maples as VP of technical operations at TGEN's CellExSys Inc. subsidiary, formerly scientific director and head of the molecular/cell processing center at...
Read More
07:00 , May 14, 2001 |  BC Week In Review  |  Company News

CellExSys scientific advisory board update

CellExSys Inc., Seattle, Wash.   Business: Gene/Cell therapy   Appointed: Lewellys Barker, chief medical officer at Sequella Global Tuberculosis Foundation; Malcolm Brenner, professor of medicine and pediatrics at Baylor College of Medicine; Nathaniel Brown, SVP...
Read More
08:00 , Mar 19, 2001 |  BC Week In Review  |  Company News

Targeted Genetics board of directors update

Appointed to the board of TGEN subsidary CellExSys Inc. : H. Stewart Parker, TGEN president and CEO, as chairman; Edward Lanphier, CEO of Sangamo BioSciences Inc ; Thomas Wiggans, president and CEO of Connetics Corp....
Read More